July 18, 2014 8:05 AM | 2 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Durata Therapeutics, Inc.(Nasdaq: DRTX) announced today that DALVANCE (dalbavancin) for injection is nowavailable for use to treat adult patients with acute bacterial skin and skinstructure infections (ABSSSI). DALVANCE was approved by the U.S. Food and DrugAdministration (FDA) on May 23, 2014 and was the first drug approved as aQualified Infectious Disease Product (QIDP). Durata began shipping DALVANCE toits distributors earlier this week. Physicians and Pharmacists may now orderDALVANCE from ASD Healthcare or their wholesaler, or they may call Durata at 1855 DURATA1 (1-855-387-2821)."DALVANCE's unique dosing regimen offers a new approach to treatment ofserious skin infections by allowing patients, healthcare professionals andhospitals to move beyond the standard daily or twice-daily IV antibioticinfusions," said Paul R. Edick, Durata's CEO. "We are very pleased thatDALVANCE is now available to millions of Americans who may benefit from thisinnovative treatment option for ABSSSI."For the six-month period of January to June 2010, a projected 9.2 millionpatients were treated in U.S. hospitals for infections of any type, and nearly17 percent of the diagnostic category presentations were for skin and skinstructure infections (SSSI). Of these presentations for SSSI, approximately 74percent were disease types included in ABSSSI. This category of infectionincreased by 176 percent from 1997 to 2009 in hospitalized patients. Themajority of skin and soft tissue infections in hospitalized patients arecaused by Staphylococcus aureus, and approximately 59 percent of theseinfections are estimated to be caused by MRSA in the U.S. Effective earlytreatment of ABSSSI is critical to prevent wound expansion and to avoidlengthy and costly hospital stays. Failure to successfully treat ABSSSI mayresult in hospital readmissions."Managing the daily treatment of ABSSSI can be a difficult task for hospitals,physicians and patients," said John Shannon, Durata's Chief CommercialOfficer. "We are very proud and excited to have hired, trained, and deployedover 100 outstanding commercial professionals to communicate the value ofDALVANCE and its unique once-a week dosing for two weeks."
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.